Advanced Crohn’s Therapies Show Similar Safety - Takeaways - MDSpire

Advanced Crohn’s Therapies Show Similar Safety

Large claims analysis finds no significant differences in serious infections, blood clots, or major cardiovascular events across biologics and a Janus kinase inhibitor.

  • By

  • Doug Brunk

  • February 19, 2026

  • 2 min

Share

  • 1

    A study of over 12,000 Crohn's disease patients found similar safety profiles among various biologics and a Janus kinase inhibitor.

  • 2

    Serious infection rates ranged from 5 to 9 events per 100 person-years, with no significant differences across therapies.

  • 3

    Ustekinumab showed a lower risk of gastrointestinal serious infections compared to vedolizumab, but no differences for extraintestinal infections.

  • 4

    Venous thromboembolism occurred at low rates of about 1 event per 100 person-years, with no significant differences between treatment groups.

  • 5

    The study had limitations, including reliance on claims data and low event rates for cardiovascular outcomes, particularly for newer agents.

Original Source(s)

Advanced Crohn’s Therapies Show Similar Safety

  • by Doug Brunk

  • February 19, 2026

Related Content

From Sophie Spitz to Molecular Melanocytoma

How one woman's pioneering research transformed pediatric melanoma diagnosis

Association Between Delivery Method and Offspring's Risk of Inflammatory Bowel Disease: A Comprehensive Systematic Review and Meta-Analysis

Comparative Effectiveness of Enteral Nutrition and Immunomodulators in Inducing and Maintaining Remission in Pediatric Crohn's Disease: A Systematic Review and Network Meta-Analysis